Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR

NCT03110978 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03110978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 26, 2017
Completion date
June 30, 2028
Enrollment
140 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung atypical carcinoid tumor, lung neuroendocrine neoplasm, lung non-small cell squamous carcinoma, minimally invasive lung adenocarcinoma, neuroendocrine carcinoma, recurrent lung adenocarcinoma, recurrent lung large cell carcinoma, recurrent lung non-small cell carcinoma, stage i lung cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage iia lung cancer ajcc v8